
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Toronto - Methicillin-resistant Staphylococcus aureus (MRSA) may cause necrotizing fasciitis, especially in areas where community acquired MRSA is prevalent, researchers say.






